Obsidian Therapeutics advances Agni-01 study with first patient enrolled in registration-enabling cohort

Summit Therapeutics expands ivonescimab programme into bladder cancer with Phase II/III trial

Phylo partners with Chugai to advance AI agents in drug discovery

Lilly secures FDA Breakthrough Therapy designation for olomorasib in pancreatic cancer

Acurx receives FDA guidance supporting ibezapolstat Phase 3 development strategy

Genprex collaborates with Roche Diagnostics on NSCLC biomarker validation

Zai Lab's zoci receives FDA orphan designation for neuroendocrine carcinomas

Biocon launches Yesafili biosimilar in US ophthalmology market

CelLBxHealth study highlights Parsortix potential in ADC biomarker monitoring

Qatar approves Zepzelca combination as first-line maintenance therapy for extensive-stage small cell lung cancer

Coiled Therapeutics doses first patient with optimised AO-252 formulation

CREATE Medicines agrees strategic research collaboration with Australia's Monash University

Ractigen Therapeutics IND application for RAG-1C receives FDA clearance

GlycoNex commences dosing in Phase I trial of GNX1021 in Japan

Datroway approved in EU for first-line metastatic triple-negative breast cancer